the aid library

LIST OPTIONS

Filter

3682

Global roadmap for research and development of tuberculosis vaccines

European & Developing Countries Clinical Trials Partnership EDCTTP; Amterdam Institute for Global health & Development aighd (2021) C1

The roadmap describes the actions needed to achieve the three development goals for TB vaccines set by the WHO: 1. A safe, effective and affordable TB vaccine for adolescents and adults. 2. An affordable TB vaccine for neonates and infants with improved safety and efficacy. 3. A therapeutic v... more

Download (155)

View PDF (192)

Covid-19 Test to Treat Guidelines
recommended

African Union; Africa CDC Centres for Disease Control and Prevention (2022) C1

n response to the outbreak, the Africa Centres for Disease Control and Prevention (Africa CDC) has been supporting African Union Member States in responding to the COVID-19 pandemic through a variety of interventions such as non-pharmaceutical interventions, quarantine, testing, isolation, contact t... more

External Link

Targeting the Mycobacterium ulcerans cytochrome bc1:aa3 for the treatment of Buruli ulcer

Scherr, N.; R. Bieri, S.S. Thomas, et al. (2018) CC

Nat Commun 9, 5370 (2018). https://doi.org/10.1038/s41467-018-07804-8. Mycobacterium ulcerans is the causative agent of Buruli ulcer, a neglected tropical skin disease that is most commonly found in children from West and Central Africa. Despite the severity of the infection, therapeutic options are... more

External Link

History, epidemiology and diagnostics of dengue in the American and Brazilian contexts: a review

Souza Salles, T.; T. da Encarnação Sá-Guimarães, E. Seam Lima de Alvarenga et al. (2018) CC

Parasites & Vectors volume 11, Article number: 264 (2018) Dengue creates a staggering epidemiological and economic burden for endemic countries. Without a specific therapy and with a commercial vaccine that presents some problems relative to its full effectiveness, initiatives to improve vector... more

External Link

Current Treatments to Control African Trypanosomiasis and One Health Perspective

Venturelli, A.; Tagliazucchi, L.; Lima, C.; Venuti, F. et al. MDPI Microorganisms (2022) CC

Human African Trypanosomiasis (HAT, sleeping sickness) and Animal African Trypanosomiasis (AAT) are neglected tropical diseases generally caused by the same etiological agent, Trypanosoma brucei. Despite important advances in the reduction or disappearance of HAT cases, AAT represents a risky reserv... more

External Link

Chromoblastomycosis: a neglected tropical disease

Scientific Electronic Library Online SciELO (2015) CC

Chromoblastomycosis (CMB) is a chronic fungal infection of the skin and the subcutaneous tissue caused by a transcutaneous traumatic inoculation of a specific group of dematiaceous fungi occurring mainly in tropical and subtropical zones worldwide. If not diagnosed at early stages, patients with CBM... more

Control and surveillance of human African trypanosomiasis: report of a WHO Expert Committee

World Health Organization WHO (2013) C_WHO

The previous report of the WHO Expert Committee on this disease followed a meeting in 1995. Intensive, coordinated efforts against HAT during the intervening 18 years have resulted in a decrease in incidence to a point at which elimination is considered feasible. This report provides informati... more

External Link

Salwa S. et al - Leishmaniasis

Salwa, S.; Amaar, A.; Baraa, A. et al (2020) C2

Leishmaniasis is a vector-borne tropical/subtropical disease caused by an intracellular parasite transmitted to humans by sand fly bite. It is endemic in Asia, Africa, the Americas, and the Mediterranean region. Worldwide reports include 1.5–2 million new cases each year, more than 300 million at ... more

Chronic Obstructive Pulmonary Disease (COPD) - Practice Essentials

Mosenifar, Z.; Brawerman, R.; Brawerman, G.; et al. Medscape (2024) CC2

The article provides a comprehensive overview of chronic obstructive pulmonary disease (COPD), covering its causes, symptoms, diagnostic methods, classification of severity, treatment options, and management strategies, with a focus on risk factors, clinical features, and therapeutic approaches such... more

External Link (199)

The diagnosis of asthma in children: An evidence-based approach to a common clinical dilemma

Masekala, R.; Risenga, S.M.; Kitchin, O.P. et al. South African Medical Journal (2018) CC

Asthma is a heterogeneous condition characterised by chronic inflammation and variable expiratory airflow limitation, as well as airway reversibility. The diagnosis of asthma in young children is limited by the inability to perform objective lung function testing in this group of patients and the wi... more

External Link

Plantes médicinales et pratiques médicales au Burkina Faso : cas des Sanan

Zerbo P., J. Millogo-Rasolodimby, O. G.Nacoulma-Ouedraogo Bois et forêts des tropiques (2011) C2

Élément culturel important, les plantes ont été utilisées pendant des siècles par les populations pour se soigner. Cependant, peu d’ethnies connaissent leur pharmacopée de par le manque d’études ethnobotaniques. La présente étude, réalisée en pays San, entité territoriale traditionn... more

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the Eur

Marx, N.; Federici, M.; Schütt, K. et al. European Heart Journal (2023) CC

Patients with diabetes are at increased risk of developing cardiovascular disease (CVD) with its manifestations of coronary artery disease (CAD), heart failure (HF), atrial fibrillation (AF), and stroke, as well as aortic and peripheral artery diseases. In addition, diabetes is a major risk factor f... more

Worldwide trends in the burden of asthma symptoms in school-aged children: Global Asthma Network Phase I cross-sectional study

Asher, I.; Rutter, C.E.; Bissell, K. et al. The Lancet (2021) CC

Asthma is the most common chronic disease in children globally. The Global Asthma Network (GAN) Phase I study aimed to determine if the worldwide burden of asthma symptoms is changing. This updated cross-sectional study used the same methods as the International study of Asthma and Allergies in Chi...ldhood (ISAAC) Phase III. Asthma symptoms were assessed from centres that completed GAN Phase I and ISAAC Phase I (1993–95), ISAAC Phase III (2001–03), or both. We included individuals from two age groups (children aged 6–7 years and adolescents aged 13–14 years) who self-completed written questionnaires at school. We estimated the 10-year rate of change in prevalence of current wheeze, severe asthma symptoms, ever having asthma, exercise wheeze, and night cough (defined by core questions in the questionnaire) for each centre, and we estimated trends across world regions and income levels using mixed-effects linear regression models with region and country income level as confounders. Overall, 119 795 participants from 27 centres in 14 countries were included: 74 361 adolescents (response rate 90%) and 45 434 children (response rate 79%). About one in ten individuals of both age groups had wheeze in the preceding year, of whom almost half had severe symptoms. Most centres showed a change in prevalence of 2 SE or more between ISAAC Phase III to GAN Phase I. Over the 27-year period (1993–2020), adolescents showed a significant decrease in percentage point prevalence per decade in severe asthma symptoms (–0·37, 95% CI –0·69 to –0·04) and an increase in ever having asthma (1·25, 0·67 to 1·83) and night cough (4·25, 3·06 to 5·44), which was also found in children (3·21, 1·80 to 4·62). The prevalence of current wheeze decreased in low-income countries (–1·37, –2·47 to –0·27], in children and –1·67, –2·70 to –0·64, in adolescents) and increased in lower-middle-income countries (1·99, 0·33 to 3·66, in children and 1·69, 0·13 to 3·25, in adolescents), but it was stable in upper-middle-income and high-income countries. Trends in prevalence and severity of asthma symptoms over the past three decades varied by age group, country income, region, and centre. The high worldwide burden of severe asthma symptoms would be mitigated by enabling access to effective therapies for asthma. more

A comprehensive review of cystic fibrosis in Africa and Asia

Abubakar, B.K.; Ahmad, U., Chau, D.M. et al. Saudi Journal of Biological Sciences (2023) CC

Cystic ﬁbrosis (CF) was earlier thought to be a disease prevalent in the West among Caucasians. However, quite a number of recent studies have uncovered CF cases outside of this region, and reported hundreds of unique and novel variant forms of CFTR. Here, we discuss the evidence of CF in parts of... more

Burden of Severe Fungal Infections in Burkina Faso

Bamba S. , Zida A., Sangaré I. et al. Journal of Fungi (2018) CC

Because of the limited access to more powerful diagnostic tools, there is a paucity of data regarding the burden of fungal infections in Burkina Faso. The aim of this study was to estimate the incidence and prevalence of serious fungal infections in this sub-Saharan country. We primarily used the na... more

External Link

Environmental Determinants of Cardiovascular Disease

Bhatnagar, A. Circulation Research (2018) CC

Many features of the environment have been found to exert an important influence on cardiovascular disease (CVD) risk, progression, and severity. Changes in the environment due to migration to different geographic locations, modifications in lifestyle choices, and shifts in social policies and cultu... more

External Link (286)

Asthma traeatment in children: A pragmatic approach

Masekela, R.; Jeevanathrum, A.; Kling, S.; et al. South African Medical Journal (2018) CC

Asthma is a heterogeneous condition characterised by chronic inflammation and variable expiratory airflow limitation, with airway reversibility. Management of chronic inflammation with anti-asthma medication improves asthma control and quality of life. The aim of this journal is to provide an eviden... more

Download (145)

View PDF (197)

COVID-19 case management capacities: diagnostics, therapeutics, vaccine readiness, and other health products – facility assessment tool: a module from the suite of health service capacity assessments

World Health Organization WHO (2021) C_WHO

Capacités de prise en charge des cas de COVID-19 : produits de diagnostic, traitements, préparation à la vaccination et autres produits de santé – outil d’évaluation des établissements

Organisation Mondiale de la Santé OMS (2021) C_WHO

module de la série d’évaluation des capacités des services de santé dans le contexte de la pandémie de COVID-19, 7 juillet 2021

Download (100)

View PDF (174)

Herramienta de evaluación de los centros de salud en materia de capacidad de gestión de casos de COVID-19

Organización Mundial de la Salud OMS (2021) C_WHO

medios de diagnóstico, tratamientos y grado de preparación respecto a las vacunas y otros productos sanitarios: módulo de las evaluaciones armonizadas de la capacidad de los centros de salud en el contexto de la pandemia de COVID-19, 7 de julio de 2021

Covid-19 Test to Treat Guidelines recommended

Covid-19 Test to Treat Guidelines
recommended